Document:

Exhibit 10.40

 

NEUROONE MEDICAL TECHNOLOGIES CORPORATION

NON-EMPLOYEE DIRECTOR COMPENSATION
POLICY

On March 29,
2018, the Board of Directors (the “Board”) of NeuroOne Medical Technologies Corporation, a Delaware
corporation (the “Company”), approved the following compensation policy (this “Policy”)
for each member of the Board who is not also serving as an employee of the Company or any of its subsidiaries (each such
member, an “Eligible Director”), effective as of January 1, 2018 (the “Effective
Date”). This policy may be amended or terminated at any time in the sole discretion of the Board or the
Compensation Committee of the Board, if any.

Annual Cash Compensation

Each Eligible Director
shall receive the annual cash compensation amounts set forth below (“Annual Cash Retainers”). Each Eligible
Director serving as a director of the Company on the Effective Date will begin earning the Annual Cash Retainers as of the Effective
Date; however, the first payment of Annual Cash Retainers (the “First Payment”) shall not be payable
until the last day of the fiscal quarter in which the Company closes a public offering or private placement of equity securities
of the Company for the account of the Company in which the gross cash proceeds to the Company at such single closing (before underwriting
discounts, commissions, fees and offering expenses) are at least three million dollars ($3,000,000) (a “Qualified Financing”).
For the avoidance of doubt, the First Payment to each Eligible Director shall consist of the Annual Cash Retainers earned by such
Eligible Director from the Effective Date through the date of the First Payment. Following the First Payment, the Annual Cash Retainers
are payable in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred.

If an Eligible
Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each
annual retainer set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount
paid for the first fiscal quarter in which the Eligible Director provides the service, and regular full quarterly payments thereafter.
All annual cash fees are vested upon payment.

 

1.       Annual Board
Service Retainer:

 

		a.	All Eligible Directors (other than Chairman of the Board):
                                         $50,000

 

		b.	Non-Executive Chairman of the Board: $100,000

 

2.       Annual Committee
Chair Service Retainer1:

 

a.       Chairman
of Audit Committee, if any: $12,500

 

b.       Chairman
of Compensation Committee, if any: $10,000

 

c.       Chairman
of Nominating & Corporate Governance Committee, if any: $10,000

 

3.       Annual Committee
Member (other than Committee Chair) Service Retainer:

 

a.       Member
of Audit Committee, if any: $5,000

 

b.       Member
of Compensation Committee, if any: $4,000

 

c.       Member
of Nominating & Corporate Governance Committee, if any: $4,000

 

 

 

1
Eligible Directors who serve as a Committee Chair will not receive the annual retainer for service as a member on
such Committee. 

    	 		 

     

    

 

Equity Compensation

The equity compensation
set forth below will be granted under the NeuroOne Medical Technologies Corporation 2017 Equity Incentive Plan (the “Plan”)
and will be documented on the applicable form of equity award agreement most recently approved for use by the Board (or a duly
authorized committee thereof) for Eligible Directors. All stock options granted under this Policy will be nonstatutory stock options,
with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying Common Stock
on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination
of service as provided in the Plan).

 

1.       Annual Equity
Award:

 

On the date of each
annual stockholder meeting of the Company commencing with the 2019 annual stockholder meeting, each Eligible Director automatically,
and without further action by the Board or Compensation Committee of the Board, if any, will be granted an annual equity award
with an aggregate value on the date of grant equal to $50,000 (the “Annual Equity Award”). One-third
of the Annual Equity Award will be issued in the form of an Option (as defined in the Plan), which will vest as follows, subject
to an Eligible Director’s Continuous Service (as defined in the Plan): 1/12th of the shares will vest monthly, commencing
on the one-month anniversary of the date of grant, so that all of the shares will be vested on the one-year anniversary of the
date of grant. Two-thirds of the Annual Equity Award will be issued in the form of a Restricted Stock Unit Award (as defined in
the Plan), which will vest as follows, subject to an Eligible Director’s Continuous Service: 1/12th of the shares will vest
monthly, commencing on the one-month anniversary of the date of grant, so that all of the shares will be vested on the one-year
anniversary of the date of grant.

 

2.       Initial Equity
Award: 

 

From and after the
2019 annual stockholder meeting, if an individual first becomes an Eligible Director other than on the date of an annual stockholder
meeting of the Company, each such Eligible Director automatically, and without further action by the Board or Compensation Committee
of the Board, if any, will be granted, on the date that he or she is first elected or appointed to the Board (or, if such date
is not a market trading day, the first market trading day thereafter), an annual equity award with an aggregate value on the date
of grant equal to the pro rata portion of the Annual Equity Award, which pro rata portion reflects a reduction for each month prior
to the date of grant that has elapsed since the preceding annual stockholder meeting of the Company (the “Pro-Rated
Annual Equity Award”). One-third of the Pro-Rated Annual Equity Award will be issued in the form of an Option, which
will vest as follows, subject to such Eligible Director’s Continuous Service: 1/12th of the shares will vest monthly, commencing
on the one-month anniversary of the date of grant, so that all of the shares will be vested on the one-year anniversary of the
date of grant. Two-thirds of the Pro-Rated Annual Equity Award will be issued in the form of a Restricted Stock Unit Award, which
will vest as follows, subject to such Eligible Director’s Continuous Service: 1/12th of the shares will vest monthly, commencing
on the one-month anniversary of the date of grant, so that all of the shares will be vested on the one-year anniversary of the
date of grant.

 

Expenses 

The Company will
reimburse Eligible Directors for ordinary, necessary and reasonable out-of-pocket travel expenses to cover in-person attendance
at and participation in Board and/or Committee meetings; provided, that Eligible Directors timely submit to the Company appropriate
documentation substantiating such expenses in accordance with the Company’s travel and expense policy, as in effect from
time to time.Exhibit 10.41

 

LOCK-UP AGREEMENT

 

This
Lock-up Agreement (this “Agreement”) is made effective as of March 1, 2018 (the “Effective
Date”) by and between Wade Fredrickson (“Shareholder”)
and NeuroOne Medical Technologies Corporation, a Delaware corporation (the
“Company”). Shareholder and the Company are hereinafter collectively referred to as the “Parties”,
and individually referred to as a “Party”. Capitalized terms used and not otherwise defined in this Agreement
shall have the respective meanings given to them in the Stock Purchase Agreements (as defined below).

 

Recitals

 

Whereas,
Shareholder and certain purchasers desire to enter into certain stock purchase agreements (the “Stock Purchase Agreements”)
pursuant to which Shareholder will sell shares of the Company’s common stock to certain purchasers (the “Purchasers”);

 

Whereas,
following the completion of the transactions contemplated by the Stock Purchase Agreements, Shareholder will beneficially own 2,613,459
shares of the Company’s common stock (the “Retained Shares”); and

 

Whereas,
as a material inducement and a condition the transaction contemplated by the Stock Purchase Agreements, the Company and the Purchasers
have requested that the Company and Shareholder enter into this Agreement.

 

Agreement

 

Now,
Therefore, in consideration of the foregoing recitals and the mutual promises and covenants herein contained, and for
other good and valuable consideration the receipt of which is hereby acknowledged, the Parties, intending to be legally bound,
hereby agree as follows:

 

1. Restrictions
on Transfer. 

 

(a) Lock-up. Shareholder
hereby agrees that Shareholder will not, subject to the exceptions set forth in this Agreement, during the period commencing on
the Effective Date and ending on eighteen (18) month anniversary of the Effective Date (the “Lock-up Period”),
(i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant
any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of the Company’s
common stock (including, for clarity, any of the Retained Shares), or any securities convertible into or exercisable or exchangeable
for the Company’s common stock, including without limitation, such other securities which may be deemed to be beneficially
owned by Shareholder (or any interest therein, including without limitation, any transfer of Shareholder’s equity interests)
in accordance with the rules and regulations of the SEC (collectively, the “Lock-up Securities”) or (ii)
enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of shares
of the Company’s common stock or such other securities, whether any such transaction described in clause (i) or (ii) of this
Section 1(a) (each, a “Transfer”) is to be settled by delivery of shares of the Company’s
common stock or such other securities, in cash or otherwise. As used in this Agreement, “beneficially own”
or “beneficial ownership” with respect to any securities means having “beneficial ownership”
of such securities as determined pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as the same may be amended
(the “Exchange Act”).

 

    	 	1	 

     

    

 

(b) Legends/Stop Orders.
Shareholder acknowledges and agrees that the Company shall be entitled to place legends on the certificates or book entry account
representing any of the Lock-up Securities and/or stop orders with the transfer agent of the Company with respect to any of the
Lock-up Securities. Upon the release of any of the Lock-up Securities from this Agreement, the Company will reasonably cooperate
with Shareholder to facilitate the timely preparation and delivery of certificates or evidence of the book entry account representing
the Lock-up Securities without such restrictive legend described above or the withdrawal of any stop transfer instructions.

 

(c) Additional Acknowledgments.
Shareholder understands that each of the Purchasers and the Company is relying upon this Agreement in proceeding toward consummation
of the transactions contemplated by the Stock Purchase Agreements. Shareholder further understands that this Agreement is irrevocable.
An attempted transfer in violation of this Agreement will be of no effect and null and void, regardless of whether the purported
transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Agreement, and will not be recorded
on the stock transfer books of the Company.

 

2. Exceptions
to lock-up. Notwithstanding the provisions of Section 1(a), during the Lock-Up Period, Shareholder may Transfer
all or a portion of the Locked-Up Shares:

 

(a) As a bona
fide gift or gifts, provided that the donee or donees thereof agree in writing, in form and substance reasonably satisfactory to
the Company, to be bound by the terms and conditions of this Agreement;

 

(b) To any trust
for the direct or indirect benefit of Shareholder or an immediate family member of Shareholder, provided that the trustee
of the trust agrees in writing, in form and substance reasonably satisfactory to the Company, to be bound by the terms and conditions
of this Agreement;

 

(c) To Shareholder’s
affiliates (including, if applicable, commonly controlled or managed investment funds) provided that such affiliate(s) agree in
writing, in form and substance reasonably satisfactory to the Company, to be bound by the terms and conditions of this Agreement;

 

(d) Pursuant to
a tender or exchange offer publicly recommended by the Company’s board of directors;

 

(e) Pursuant to
a merger, stock sale, consolidation or other transaction publicly recommended by the Company’s board of directors;

 

(f) By will or
other testamentary document or by intestacy;

 

    	 	2	 

     

    

 

(g) Commencing
six (6) months after the Effective Date, to any third party or parties, including a disposition for value, provided that
such third party or parties agree(s) in writing, in form and substance reasonably satisfactory to the Company, to be bound by the
terms and conditions of this Agreement, and provided further that each such third party or parties shall be deemed not to
be an underwriter of the Locked-Up Shares so sold within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended
(the “33 Act”);

 

(h) Commencing
six (6) months after the Effective Date, to any third party in a transaction exempt from the registration requirements of the 33
Act pursuant to Section 4(a)(4) thereof, an amount of the Locked-Up Shares equal to or less than 1% of the average weekly reported
volume of trading of the Company’s common stock on all national securities exchanges and/or reported through the automated
quotation system of a registered securities association during the four calendar weeks preceding the date of receipt of the order
to execute the transaction by the broker or the date of execution of the transaction directly with a market maker;

 

(i) Pursuant to
and to the extent the Company grants an exception to the lock-up provisions of any other person subject to a lock-up agreement
with it, the Company shall provide a substantially similar exception to Shareholder hereunder; and/or

 

(j) If the first
closing on a financing resulting in a minimum of $3 million in gross proceeds to the Company has not occurred by June 30, 2018.

 

For purposes hereof,
“immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin,
“affiliate” shall mean, as applied to any entity, any other entity directly or indirectly controlling, controlled
by, or under direct or indirect common control with, such entity (for purposes hereof, “control” (including,
with correlative meanings, the terms “controlling,” “controlled by” and “under common
control with”), as applied to any entity, means the possession, directly or indirectly, of the power to direct or cause
the direction of the management and policies of such entity, whether through the ownership of voting securities, by contract or
otherwise), and “person” shall mean any individual, corporation, partnership, limited liability company, trust,
joint venture, governmental entity or other unincorporated entity, association or group.

 

3. Standstill.

 

(a) Current Holdings.
Shareholder hereby represents and warrants that, as of the date hereof, Shareholder does not have, directly or indirectly, beneficial
ownership of securities, or rights or options to own, acquire or vote any such securities (through purchase, exchange, conversion
or otherwise), of the Company, other than the Retained Shares.

 

    	 	3	 

     

    

 

(b) Standstill Restrictions.
During the Lock-up Period, except as specifically permitted under an executed definitive agreement entered into between Shareholder
and the Company, Shareholder will not, and will cause each of his affiliates and his and their respective representatives and any
other agents acting on its or their behalf, or other persons or entities acting in concert with Shareholder or his affiliates,
not to, directly or indirectly, (i) make, effect or commence any tender or exchange offer, merger or other business combination
involving the Company, (ii) commence or complete, or propose to commence or complete, any recapitalization, restructuring, liquidation,
dissolution or other extraordinary transaction with respect to the Company, (iii) make, or in any way participate in, any “solicitation”
of proxies to vote or consent, or seek to advise or influence any person with respect to the voting of, any securities of the Company
(all within the meaning of Section 14 of the Exchange Act), (iv) form, join or in any way participate in a “group”
(within the meaning of Section 13(d)(3) of the Exchange Act) with respect to, or otherwise act in concert with any person in respect
of, any securities of the Company, (v) otherwise act, alone or in concert with others, to seek representation on or to control
or influence the management, the Board of Directors of the Company or policies of the Company, (vi) negotiate with or provide any
information to any person with respect to, or make any statement or proposal to any person with respect to, or make any public
announcement or proposal or offer whatsoever with respect to, or act as a financing source for or otherwise invest in any other
persons in connection with, or otherwise solicit, seek or offer to effect any transactions or actions described in the foregoing
clauses (i) through (vi), or make any other proposal inconsistent with the terms of this Agreement or that otherwise could reasonably
be expected to result in a public announcement regarding any such transactions or actions, (vii) advise, assist, or encourage any
other persons in connection with any of the foregoing; or (viii) make any statement or proposal to the Board of Directors of the
Company, any of the Company’s representatives or any of the Company’s stockholders regarding, or make any public announcement,
proposal or offer, with respect to, or otherwise solicit, seek or offer to effect, any request or proposal to waive, terminate
or amend the provisions of this Agreement, unless and until, in the case of each of the foregoing clauses (i) through (viii), Shareholder
has received the prior written invitation or approval of the Board of Directors of the Company to do so or the transaction or action
falls within the scope of one of the exceptions to the Lock-Up provided for in Section 2 above.

 

4. Ownership
of Shares; Voting Rights. During the Lock-up Period, Shareholder shall retain all rights of ownership in the Retained
Shares, including voting rights and the right to receive any dividends that may be declared in respect thereof and paid in cash
or shares of the Company’s common stock (in each case, a “Dividend”). Any shares of the Company’s
common stock issued to Shareholder during the Lock-up Period (a) as a Dividend (other than in connection with a stock split, whether
effected directly or through a Dividend), or (b) upon reinvestment of a Dividend through the Company’s dividend reinvestment
program, shall not be subject to the terms of this Agreement.

 

5. Miscellaneous.

 

(a) Further Assurances.
From time to time until the expiration of the Lock-up Period, at the Company’ss request and without further consideration,
Shareholder shall execute and deliver such additional documents and take all such further lawful action as may be necessary or
desirable to consummate and make effective, in the most expeditious manner practicable, the transactions contemplated by this Agreement.

 

(b) Specific Performance.
Each of the Parties agrees, recognizes and acknowledges that a breach by it of any covenants or agreements contained in this Agreement
will cause the other parties to sustain damages for which they would not have an adequate remedy at law for money damages, and
therefore each of the Parties agrees that in the event of any such breach any aggrieved Party shall be entitled to the remedy of
specific performance of such covenants and agreements (without any requirement to post bond or other security and without having
to prove actual damages) and injunctive and other equitable relief in addition to any other remedy to which it may be entitled,
at law or in equity.

 

    	 	4	 

     

    

 

(c) Remedies Cumulative.
All rights, powers and remedies provided under this Agreement or otherwise available in respect hereof at law or in equity shall
be cumulative and not alternative, and the exercise of any such rights, powers or remedies by any Party shall not preclude the
simultaneous or later exercise of any other such right, power or remedy by such Party.

 

(d) Amendment and
Modification. No amendment or modification or addition to this Agreement will be valid or effective unless the same is in writing
and signed by each of the Parties.

 

(e) Assignability;
Third Party Rights.

 

(i) This Agreement
shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors
and permitted assigns; provided, that neither this Agreement nor any of the rights or obligations of any Party hereunder
may be assigned or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or
delegation of this Agreement or any of such rights or obligations by any Party without the other Party’s prior written consent
shall be void and of no effect.

 

(ii) Nothing in this
Agreement is intended to or shall confer upon any person (other than the Parties hereto) any right, benefit or remedy of any nature
whatsoever under or by reason of this Agreement.

 

(f) Entire Agreement;
Counterparts; Exchanges by Facsimile. This Agreement constitutes the entire agreement, and supersede all prior agreements and
understandings, both written and oral, among or between any of the Parties with respect to the subject matter of this Agreement,
other than the Stock Purchase Agreements. This Agreement may be executed in several counterparts, each of which shall be deemed
an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts
or otherwise) by facsimile or by electronic delivery in .pdf format shall be sufficient to bind the Parties to the terms and provisions
of this Agreement.

 

(g) Notices. All
notices, demands, consents, requests, instructions and other communications to be given or delivered or permitted under or by reason
of the provisions of this Agreement or in connection with the transactions contemplated hereby shall be in writing and shall be
deemed to be delivered and received by the intended recipient as follows: (i) if personally delivered, on the business day of such
delivery (as evidenced by the receipt of the personal delivery service); (ii) if mailed certified or registered mail return receipt
requested, two (2) business days after being mailed; or (iii) if delivered by overnight courier (with all charges having been prepaid),
on the business day of such delivery (as evidenced by the receipt of the overnight courier service of recognized standing). If
any notice, demand, consent, request, instruction or other communication cannot be delivered because of a changed address of which
no notice was given (in accordance with this Section 4(g), or the refusal to accept the same, the notice, demand, consent,
request, instruction or other communication shall be deemed received on the second business day the notice is sent (as evidenced
by a sworn affidavit of the sender). All such notices, demands, consents, requests, instructions and other communications will
be sent to the following addresses or facsimile numbers as applicable:

 

	

If to the Company to:
	 	
        NeuroOne Medical Technologies
        Corporation

        10006 Liatris Lane

        Eden Prairie, Minnesota 55347

        Attention: David A. Rosa

 

    	 	5	 

     

    

 

	
        With copies to:

         

         

         

         

         

        If to Shareholder to:

         

         

         

        With copies to:
	 	
        Honigman Miller Schwartz
        and Cohn LLP

        350 East Michigan Avenue,
        Suite 300

        Kalamazoo, Michigan 49007

        Attention: Phillip D.
        Torrence, Esq.

        Fax: 269.337.7703

         

        Wade Fredrickson

        4825 Suburban Drive

        Shorewood, Minnesota 55331

         

        Nilan Johnson Lewis PA

        120 South Sixth Street,
        Suite 400

        Minneapolis, Minnesota 55402

        Attention: John C. Levy

        Fax: 612.305.7501

 

Any such person may by notice given in
accordance with this Section 4(g) to the other parties hereto designate another address or person for receipt by such person
of notices hereunder.

 

(h) Titles
and Captions. All Section titles or captions in this Agreement are for
convenience only. They shall not be deemed part of this Agreement and do not in any way define, limit, extend or describe the scope
or intent of any provisions hereof.

 

(i) Further
Action. The parties shall execute and deliver all documents, provide
all information and take or forbear from taking all such action as may be necessary or appropriate to achieve the purposes of
this Agreement. Each Party shall bear its own expenses in connection therewith.

 

(j) Governing Law;
Consent to Jurisdiction, Waiver of Jury Trial. This Agreement will be governed by and construed in accordance with the internal
laws of the State of Delaware, without regard to its principles of conflicts of laws. Each of the Parties hereto irrevocably submits
to the exclusive jurisdiction of the state and federal courts sitting in the State of Minnesota for the purpose of any suit, action,
proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby.  Service of
process in connection with any such suit, action or proceeding may be served on each Party hereto anywhere in the world by the
same methods as are specified for the giving of notices under this Agreement.  Each of the Parties hereto irrevocably consents
to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court.  Each
Party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts
and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient
forum.  EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT
AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

(k) Creditors.
None of the provisions of this Agreement shall be for the benefit of or enforceable by creditors of any Party.

 

(l) Waiver.
 No failure by any Party to insist upon the strict performance of any covenant, agreement, term or condition
of this Agreement or to exercise any right or remedy available upon a breach thereof shall constitute a waiver of any such breach
or of such or any other covenant, agreement, term or condition.

 

(m) Attorney’s
Fees. If any dispute arises with respect to the enforcement, interpretation, or application of this Agreement and costs are
incurred to resolve such dispute, the prevailing party in such dispute shall recover from the non-prevailing party all costs and
expenses, including reasonable attorneys’ fees, incurred by the prevailing party in such dispute.

 

Signatures
on the Following Page

 

    	 	6	 

     

    

 

In
Witness Whereof, the Parties have executed this Agreement as of the Effective Date.

 

	

Shareholder:
	 	The Company:
	 	 	 
	 	 	NeuroOne Medical Technologies Corporation
	 	 	 	 
	/s/ Wade Fredrickson	 	By:	/s/ Dave Rosa
	Wade Fredrickson	 	Name:	Dave Rosa
	 	 	Title:	CEO and President

 

Signature
Page 

to
Lock-up Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}]]